ClinicalTrials.gg
Not yet recruitingNCT07207980CREDOenAPUpdated Oct 6, 2025

Lifestyle Intervention for Type 2 Diabetes in Primary Care (CREDOenAP)

An interventional study of CREDOenAP intervention in Type 2 Diabetes Mellitus (T2DM), sponsored by Parc Sanitari Pere Virgili. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-06.

Sponsored by Parc Sanitari Pere Virgili · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.

Planned enrollment
307th of 383
120 · median 484
Started
2026
with 23 others
No phase
77 of 429
17 open now
Primary completion
2027-06
later than 24 of 54 live
Registered
402nd of 429
by date

Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 307th largest by planned enrollment of the 383 interventional ones that give a count, is one of 24 that started in 2026, is one of 77 with no phase, reaches primary completion later than 24 of the 54 other live ones, and was the 402nd registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to determine whether an intensive lifestyle intervention can achieve remission of type 2 diabetes mellitus (T2DM) in adult patients treated in primary care. The main questions the study seeks to answer are:

  • What proportion of participants achieve diabetes remission after 6 months of intervention?
  • How many participants maintain remission 12 months after completing the program (18 months total)?

Participants will:

  • Follow a personalized dietary plan with carbohydrate restriction.
  • Engage in moderate, accessible physical activity.
  • Implement strategies to improve circadian rhythm regularity.
  • Receive psychological counseling and support.
03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Type 2 Diabetes Mellitus (T2DM)
  • Diabetes Remission
  • Lifestyle Intervention
  • Primary Care
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Men and women aged 18-80 years, inclusive.
  3. Confirmed diagnosis of T2DM according to recognized diagnostic criteria
  4. Most recent recorded (HbA1c) > 6.5%.
  5. (BMI) greater than 27 kg/m².

Exclusion criteria

Exclusion Criteria:

  1. Failure to meet the diagnostic criteria for T2DM in the screening laboratory tests.
  2. Being dependent for basic activities of daily living (Barthel score ≤ 90 points).
  3. Lack of willingness to cooperate with the follow-up of the lifestyle intervention plan.
  4. Presence of serious or terminal comorbidities significantly worsening short- to medium-term prognosis (active cancer, terminal chronic diseases, myocardial infarction within the last 6 months, acute heart failure or stage ≥ III, etc.).
  5. History of ketoacidosis.
  6. Presence of criteria or potential insulinopenia (abnormal C-peptide, anti-GAD+ antibodies, pattern of basal and/or glucose-stimulated hypoinsulinemia).
  7. Cognitive impairment.
  8. Weight loss exceeding 5 kg in the past 6 months.
  9. Significant changes in physical activity and/or dietary patterns in the past 6 months.
  10. History of eating disorders.
  11. History of substance abuse.
  12. History of severe psychiatric disorders.
  13. Pregnancy or intention to become pregnant within the study period.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Intervention group

    The program consists of biweekly in-person and telephone visits, focused on implementing a personalized dietary plan with carbohydrate restriction, based on the American Diabetes Association recommendations; moderate and accessible physical activity; circadian rhythm regularization; and psychological counseling and support.

    Behavioral: CREDOenAP intervention

  • No intervention
    Control group

    They will receive the standard clinical treatment for diabetes

Interventions

  • BehavioralCREDOenAP intervention

    Intervention program with intensive lifestyle counseling, added to standard pharmacological treatment subsequently adjusted according to clinical needs and outcomes. The intervention will last 6 months and consists of biweekly in-person and telephone visits. Patients will follow a personalized dietary plan with carbohydrate restriction, based on the recommendations of the American Diabetes Association; engage in moderate and accessible physical activity; implement circadian rhythm regularization; and receive psychological counseling and support.

06

What researchers measure

Primary outcomes

  1. Presence of T2DM remission

    Glycated hemoglobin (HbA1c): T2DM remission will be considered if HbA1c is \< 6.5% after 6 months of intervention and at least 3 months without antidiabetic medication. HbA1c will be determined by blood analysis after a minimum of 8 hours of fasting Fasting plasma glucose: T2DM remission will be considered if fasting venous plasma glucose is \< 126 mg/dL after 6 months of intervention and at least 3 months without antidiabetic medication. Fasting plasma glucose will be measured by venous blood analysis after a minimum of 8 hours of fasting

    Time frame: After 6 months of intervention and 12 months after the intervention

Secondary outcomes

  1. Blood pressure

    Blood pressure will be measured three times after the participant has been seated at rest for 10 minutes with uncrossed legs. The mean of the last two measurements will be used for statistical analysis. Systolic and diastolic blood pressure will be reported in mmHg using a brachial cuff sphygmomanometer.

    Time frame: After 6 months of intervention and 12 months after the intervention.

  2. Total cholesterol

    Measured in mg/dL via blood analysis.

    Time frame: After 6 months of intervention and 12 months after the intervention

  3. HDL cholesterol

    High-density lipoprotein (HDL) cholesterol measured in mg/dL via blood analysis.

    Time frame: After 6 months of intervention and 12 months after the intervention

  4. LDL cholesterol

    Low-density lipoprotein (LDL) cholesterol measured in mg/dL via blood analysis.

    Time frame: After 6 months of intervention and 12 months after the intervention

  5. Apolipoprotein B100 (ApoB100)

    A protein involved in cholesterol transport and relevant for evaluating elevated cholesterol causes, measured in mg/dL via blood analysis.

    Time frame: After 6 months of intervention and 12 months after the intervention

  6. Triglycerides

    Measured in mg/dL via blood analysis

    Time frame: After 6 months of intervention and 12 months after the intervention

  7. Presence and size of atherosclerotic plaques in carotid arteries

    Assessed via Doppler ultrasound of the supraaortic trunks. If plaques are present, the total plaque area will be measured in cm², and changes in plaque area will be tracked throughout the study.

    Time frame: After 6 months of intervention and 12 months after the intervention

  8. Weight

    Measured in kilograms (kg)

    Time frame: After 6 months of intervention and 12 months after the intervention

  9. Body Mass Index (BMI)

    Calculated from weight and height using the formula: BMI = weight (kg) / \[height (m)\]².

    Time frame: After 6 months of intervention and 12 months after the intervention

  10. Abdominal circumference

    Measured at the midpoint between the lowest rib and the iliac crest during maximal inspiration and expiration, in centimeters (cm)

    Time frame: After 6 months of intervention and 12 months after the intervention

  11. Insulin resistance

    Evaluated using the HOMA-IR index (Homeostasis Model Assessment of Insulin Resistance), which estimates insulin resistance and beta-cell function. Determined via blood analysis after a minimum 8-hour fast. Values above 2.5 may indicate T2D. Calculated as: \[fasting insulin (μU/mL) x glucemia basal (mmol/L)\] / 22.5 = \[fasting insulin (μU/mL) x (Glucemia basal (mg/dL) x 0,0555)\] / 22.5

    Time frame: After 6 months of intervention and 12 months after the intervention

  12. Pancreatic activity

    Assessed using the HOMA-B index, which evaluates the function and activity of pancreatic beta cells. HOMA-B, together with HOMA-IR, helps in the diagnosis of T2D. Values between 167 and 175 are considered normal and not indicative of T2D. Values below this range suggest impaired beta-cell function, resulting in insufficient insulin production (insulinopenia).

    Time frame: After 6 months of intervention and 12 months after the intervention

  13. Fasting insulin

    Measures the amount of insulin in a blood sample. Insulin is a hormone produced by the pancreas. Normal values range between 5-25 U/mL. It will be measured via blood analysis after a minimum 8-hour fast.

    Time frame: After 6 months of intervention and 12 months after the intervention

  14. Metabolic Syndrome Diagnosis

    Metabolic Syndrome Diagnosis is established if at least three of the following five criteria are present: * Abdominal circumference: Men of European descent \> 94 cm; Women of European descent \> 80 cm. For other ethnicities, cut-off points are defined according to the International Diabetes Federation (IDF). (López De La Torre et al., 2010) * Fasting glucose: \> 100 mg/dL or receiving pharmacological treatment for hyperglycemia. * Triglycerides: \> 150 mg/dL or receiving lipid-lowering therapy. * HDL cholesterol: \< 40 mg/dL in men; \< 50 mg/dL in women, or receiving lipid-lowering therapy. * Blood pressure: Systolic \> 130 mmHg or Diastolic \> 85 mmHg, or receiving antihypertensive treatment.

    Time frame: After 6 months of intervention and 12 months after the intervention

  15. NAFLD Liver Fat Score

    Non-alcoholic fatty liver disease (NAFLD) is a condition characterized by excessive fat accumulation in the liver. Its severity can vary according to the score: \< -1.455 low risk, -1.455 to 0.675 intermediate risk, \> 0.675 high risk (Angulo et al., 2007; Kotronen et al., 2009). The calculation is determined using the following formula: -2.89 + 1.18 × Metabolic Syndrome (Yes = 1 / No = 0) + 0.45 × T2DM (Yes = 2 / No = 0) + 0.15 × Fasting Insulin (mU/L) + 0.04 × Fasting Serum AST (U/L) - 0.94 × AST/ALT ratio

    Time frame: After 6 months of intervention and 12 months after the intervention

  16. NAFLD Fibrosis Score

    The identification and quantification of fibrosis are clinically relevant since fibrosis is associated with an unfavorable clinical prognosis. An NFS \> 0.676 indicates the presence of advanced fibrosis (Angulo et al., 2007; Kotronen et al., 2009). The calculation is determined using the following formula: -1.675 + 0.037 × Age (years) + 0.094 × BMI (kg/m²) + 1.13 × IFG/diabetes (Yes = 1 / No = 0) + 0.99 × AST/ALT ratio - 0.013 × Platelets (×10⁹/L) - 0.66 × Albumin (g/dL)

    Time frame: After 6 months of intervention and 12 months after the intervention

  17. Physical activity

    Physical activity will be assessed using the International Physical Activity Questionnaire (IPAQ)

    Time frame: After 6 months of intervention and 12 months after the intervention

  18. Nutritional and energy composition:

    The 24-hour dietary recall questionnaire will be administered at each biweekly visit

    Time frame: After 6 months of intervention and 12 months after the intervention

  19. Smoking habits

    Measured by a study-specific questionnaire

    Time frame: After 6 months of intervention and 12 months after the intervention

  20. Alcohol consumption

    Alcohol intake will be quantified using a questionnaire combined with a standardized alcohol unit conversion calculator

    Time frame: After 6 months of intervention and 12 months after the intervention

  21. Circadian habits

    Measured by a study-specific questionnaire

    Time frame: After 6 months of intervention and 12 months after the intervention

  22. Health status

    SF-36: This is a generic scale that provides a health status profile and is applicable both to patients and to the general population

    Time frame: After 6 months of intervention and 12 months after the intervention

  23. Medication consumption

    Defined Daily Dose (DDD) by active substance: DDDs of the active substances consumed will be classified according to ATC7. Each ATC classification has a defined daily dose based on international standards, which determine the recommended maximum daily amount for the approved indication of the active substance

    Time frame: After 6 months of intervention and 12 months after the intervention

  24. Number of hypoglycemia episodes

    Episodes of hypoglycemia detected by patients through capillary blood glucose levels and/or recorded in eCAP during the intervention (plasma glucose \<60 mg/dl)

    Time frame: During each follow-up telephone visit throughout the intervention, after 6 months of intervention and 12 months after the intervention

  25. Number of symptomatic hyperglycemia episodes

    Episodes of hyperglycemia recorded in eCAP during the intervention (plasma glucose \>350 mg/dl accompanied by compatible symptoms such as general malaise, nausea, asthenia, among others)

    Time frame: During each follow-up telephone visit throughout the intervention, after 6 months of intervention and 12 months after the intervention

  26. Total number of healthcare visits

    Annual contacts with the healthcare system including Primary Care (physicians and nursing), Specialized Care, and Emergency Care

    Time frame: During each follow-up telephone visit throughout the intervention, after 6 months of intervention and 12 months after the intervention

  27. Number of diabetes-related emergency episodes

    Emergency visits related to diabetes during the intervention period

    Time frame: During each follow-up telephone visit throughout the intervention, after 6 months of intervention and 12 months after the intervention

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jun 2027, 17 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 17 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Oct 6, 2025
StartEst.
Jan 11, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jan 11, 2028
Last update
Oct 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07207980
Lead sponsor
Parc Sanitari Pere Virgili
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Jan 11, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Jan 11, 2028 (estimated)
Last update
Oct 6, 2025

Study contacts

Alexandre Ternianov Principal investigator
Contact
aternianov@perevirgili.cat
+34 932 21 37 85
Alexandre Ternianov
principal investigator · Parc Sanitari Pere Virgili

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion